RU2000100373A - NATURAL ANTITUMOR OR ANTIVIRAL SUBSTANCES AND THEIR APPLICATION - Google Patents

NATURAL ANTITUMOR OR ANTIVIRAL SUBSTANCES AND THEIR APPLICATION

Info

Publication number
RU2000100373A
RU2000100373A RU2000100373/04A RU2000100373A RU2000100373A RU 2000100373 A RU2000100373 A RU 2000100373A RU 2000100373/04 A RU2000100373/04 A RU 2000100373/04A RU 2000100373 A RU2000100373 A RU 2000100373A RU 2000100373 A RU2000100373 A RU 2000100373A
Authority
RU
Russia
Prior art keywords
antitumor
pharmaceutically acceptable
acceptable salt
antiviral
methoxy group
Prior art date
Application number
RU2000100373/04A
Other languages
Russian (ru)
Other versions
RU2205010C2 (en
Inventor
Цунеацу МОРИ
Маову ГУО
Ецуко МОРИ
Original Assignee
Матаеси Девелопмент Ко., Лтд.
Цунеацу МОРИ
МОРИ Такахиде
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Матаеси Девелопмент Ко., Лтд., Цунеацу МОРИ, МОРИ Такахиде filed Critical Матаеси Девелопмент Ко., Лтд.
Publication of RU2000100373A publication Critical patent/RU2000100373A/en
Application granted granted Critical
Publication of RU2205010C2 publication Critical patent/RU2205010C2/en

Links

Claims (8)

1. Противоопухолевое или противовирусное вещество, представленное формулой (1)
Figure 00000001

где R1 представляет собой группу
Figure 00000002

и R2 представляет собой метоксигруппу, или его фармацевтически приемлемая соль.1. An antitumor or antiviral substance represented by the formula (1)
Figure 00000001

where R1 represents a group
Figure 00000002

and R2 represents a methoxy group, or a pharmaceutically acceptable salt thereof. 2. Фармацевтический препарат, отличающийся тем, что включает в себя в качестве эффективного ингредиента противоопухолевое или противовирусное вещество, представленное формулой (1)
Figure 00000003

где R1 представляет собой группу
Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

R2 представляет собой атом водорода, гидроксильную группу или метоксигруппу, или его фармацевтически приемлемую соль.2. A pharmaceutical preparation, characterized in that it includes, as an effective ingredient, an antitumor or antiviral substance represented by the formula (1)
Figure 00000003

where R1 represents a group
Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

R2 represents a hydrogen atom, a hydroxyl group or a methoxy group, or a pharmaceutically acceptable salt thereof. 3. Фармацевтический препарат по п. 2, отличающийся тем, что R1 и R2, соответственно, представляют собой
Figure 00000008

и атом водорода,
Figure 00000009

и гидроксильную группу,
Figure 00000010

и метоксигруппу,
Figure 00000011

и атом водорода,
Figure 00000012

и метоксигруппу, или
Figure 00000013

и метоксигруппу.3. The pharmaceutical preparation according to claim 2, characterized in that R1 and R2, respectively, are
Figure 00000008

and a hydrogen atom,
Figure 00000009

and a hydroxyl group,
Figure 00000010

and methoxy group,
Figure 00000011

and a hydrogen atom,
Figure 00000012

and a methoxy group, or
Figure 00000013

and a methoxy group. 4. Противоопухолевый или противовирусный агент, отличающийся тем, что включает в себя в качестве эффективного ингредиента противоопухолевое или противовирусное вещество по п. 2 или 3, или его фармацевтически приемлемую соль. 4. An antitumor or antiviral agent, characterized in that it includes as an effective ingredient the antitumor or antiviral substance according to claim 2 or 3, or a pharmaceutically acceptable salt thereof. 5. Способ получения противоопухолевого или противовирусного вещества по п. 2 или 3, или его фармацевтически приемлемой соли, отличающийся тем, что культивируют клетку, полученную из отпадающей плаценты (placenta decidua) человека и обладающую способностью продуцировать вещество, представленное формулой (1) по п. 2, собирают из культуральной жидкости вещество, представленное формулой (1), и, если необходимо, превращают его в фармацевтически приемлемую соль. 5. A method of obtaining an antitumor or antiviral substance according to claim 2 or 3, or a pharmaceutically acceptable salt thereof, characterized in that the cell is cultured from a decanting placenta (placenta decidua) of a person and having the ability to produce a substance represented by the formula (1) according to claim .2, the substance represented by the formula (1) is collected from the culture fluid and, if necessary, converted into a pharmaceutically acceptable salt. 6. Культура СD57-положительных, HLA. DR-сильно положительных природных клетка-супрессор человеческого типа. 6. Culture CD57-positive, HLA. DR is a strongly positive natural human-type suppressor cell. 7. Способ супрессии опухоли или вируса, отличающийся тем, что пациенту, нуждающемуся в супрессии опухоли или вируса, вводят эффективное количество противоопухолевого или противовирусного вещества по п. 2 или 3, или его фармацевтически приемлемой соли. 7. A method of suppressing a tumor or virus, characterized in that a patient in need of suppressing a tumor or virus is administered an effective amount of an antitumor or antiviral substance according to claim 2 or 3, or a pharmaceutically acceptable salt thereof. 8. Противоопухолевое или противовирусное вещество по п. 2 или 3, или его фармацевтически приемлемая соль для получения противоопухолевого или противовирусного агента. 8. The antitumor or antiviral substance according to claim 2 or 3, or a pharmaceutically acceptable salt thereof, for the preparation of an antitumor or antiviral agent.
RU2000100373/14A 1997-06-03 1998-06-02 Natural antitumor or antiviral substances and their application RU2205010C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/159321 1997-06-03
JP15932197 1997-06-03

Publications (2)

Publication Number Publication Date
RU2000100373A true RU2000100373A (en) 2002-01-10
RU2205010C2 RU2205010C2 (en) 2003-05-27

Family

ID=15691258

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000100373/14A RU2205010C2 (en) 1997-06-03 1998-06-02 Natural antitumor or antiviral substances and their application

Country Status (13)

Country Link
US (1) US6498149B1 (en)
EP (1) EP0997473B1 (en)
JP (1) JP3193061B2 (en)
KR (1) KR100404630B1 (en)
CN (2) CN1292073C (en)
AT (1) ATE236922T1 (en)
AU (1) AU754370B2 (en)
CA (1) CA2294158C (en)
DE (1) DE69813231T2 (en)
ES (1) ES2194320T3 (en)
HK (2) HK1029121A1 (en)
RU (1) RU2205010C2 (en)
WO (1) WO1998055493A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488591C2 (en) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Azacytidine analogues and use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098355C (en) * 2000-09-12 2003-01-08 华东理工大学 Acetyl-tyrothricin and process for preparing 5-fluorouridine using same as enzyme precursor
KR100828453B1 (en) * 2001-01-22 2008-05-13 머크 앤드 캄파니 인코포레이티드 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP2009541437A (en) 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Therapeutic compounds
ES2361886T3 (en) 2006-06-27 2011-06-24 Cbt Development Limited 2 ', 3'-METHYLIDY ADENOSINE PROMOTES NEW FOR USE AS PROPHARMES FOR ADENOSINE RECEIVER AGONISTS.
FI20096394A0 (en) 2009-12-23 2009-12-23 Valtion Teknillinen DETECTING DETECTION IN COMMUNICATIONS NETWORKS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564518A (en) * 1978-11-07 1980-05-15 Taiho Yakuhin Kogyo Kk Carcinostatic composition
JPS54129131A (en) * 1978-03-27 1979-10-06 Taiho Pharmaceutical Co Ltd Antiimalignant tumor agent composition
JPS61291595A (en) * 1985-06-19 1986-12-22 Ajinomoto Co Inc Production of 2'-0-methylated rna
JPS6214794A (en) * 1985-07-09 1987-01-23 Ajinomoto Co Inc Production of guanosine and/or inosine by fermentation
JPS6223725A (en) 1985-07-24 1987-01-31 Sekisui Plastics Co Ltd Apparatus for preparation of foamed shape of thermoplastic resin
JPS6223723A (en) 1985-07-24 1987-01-31 Canon Inc Process for injection and compression molding
JPH01125325A (en) * 1987-11-11 1989-05-17 Agency Of Ind Science & Technol Antitumor agent
US5200514A (en) * 1990-01-19 1993-04-06 University Of Georgia Research Foundation, Inc. Synthesis of 2'-deoxypyrimidine nucleosides
JPH0695946B2 (en) * 1991-01-23 1994-11-30 日本製紙株式会社 Uridine production method
US5580973A (en) * 1994-01-07 1996-12-03 Lee-Ruff; Edward Process for preparing optically active nucleosides from chiral cyclobutanones

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488591C2 (en) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Azacytidine analogues and use thereof

Similar Documents

Publication Publication Date Title
CA2015996A1 (en) Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
RU93055137A (en) HETEROCYCLO-CYCLIC DERIVATIVES OF AMINES, METHOD OF OBTAINING, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
RU97115713A (en) COMPOUNDS CONTAINING PETROPYRANES AND METHOD OF APPLICATION
CA2333965A1 (en) Method of enhancing lysosomal .alpha.-galactosidase a
RU93053630A (en) NEW STEROIDS, METHOD FOR PRODUCING THEM, PHARMACEUTICAL DRUG, METHOD OF TREATMENT
RU2000131178A (en) METABOLITES OF ECEINASCIDIN 743
DK208987A (en) POLYPEPTIDES AND ANTIBODIES CHARACTERISTIC FOR PAPILLOMVIRUS AND THEIR USE IN DIAGNOSTIC METHODS AND IN VACCINES
EP0271795A3 (en) Octahydro-10-oxo-6H-pyridazo[1,2-a][1,2]diazepin derivatives, intermediates and process for their preparation, and medicament containing them
RU2000100373A (en) NATURAL ANTITUMOR OR ANTIVIRAL SUBSTANCES AND THEIR APPLICATION
RU96109699A (en) GUANIDIDES OF ALKENILKARBONIC ACIDS, METHOD OF THEIR RECEIVING, CONTAINING THEIR MEDICATION OR DIAGNOSTIC TOOL
CA2437851A1 (en) 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
Clancy Isolation and kinetic characteristics of mucosal lymphocytes in Crohn's disease
SE8904298D0 (en) NEW COMPOUNDS
RU94013440A (en) DERIVATIVES 3-DEZOXYOLYSACCHARIDES, METHODS OF THEIR RECEIVING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
ATE237343T1 (en) RETROPEPTIDES, ANTIBODIES AGAINST THEM AND THEIR USES IN VACCINATION AND IN VITRO DIAGNOSTICS
EA199800865A1 (en) BENZOTIOPHENES CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH THEIR USE
KR900011717A (en) Phenylhydrazone, methods for their preparation, and therapeutic and cosmetic compositions prepared therefrom
NZ294878A (en) Water soluble derivatives of epipodophyllotoxin and medicaments
EP1352955A3 (en) HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
SE8704436D0 (en) USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS
KR890012942A (en) 5-substituted ornithine derivatives
RU2004102398A (en) BENZO [G] Quinoline Derivatives for the Treatment of Glaucoma and Myopia
ES2194320T3 (en) NATURAL ANTIVIRAL OR ANTITUMURAL SUBSTANCES AND USE OF THE SAME.
CA2045761A1 (en) Ws7622a mono- or di- sulfate, process for preparation thereof and use thereof